Management of Crohn's disease in poor responders to adalimumab

Clinical and Experimental Gastroenterology

Volumn 7, Issue 1, 2014, Pages 83-92

  de Boer, Nanne K H ^a   Löwenberg, Mark ^b   Hoentjen, Frank ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti TNF; Biological; Inflammatory bowel disease; Infliximab; Loss of response

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; C REACTIVE PROTEIN; CALGRANULIN; CIPROFLOXACIN; DRUG ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; NATALIZUMAB; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; VEDOLIZUMAB;

ANAPHYLAXIS; ANTIBODY TITER; ANUS FISTULA; COLONOSCOPY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; LOADING DRUG DOSE; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; PATIENT COMPLIANCE; REMISSION; RETREATMENT; REVIEW; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT;

EID: 84898473238     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S47627     Document Type: Review

References (49)

1. Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133(2):412-422.
2. van Dullemen HM, van Deventer SJ, Hommes DW, etal. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109(1):129-135.
3. Burness CB, Keating GM. Adalimumab: a review of its use in the treatment of patients with ulcerative colitis. Bio Drugs. 2013;27(3):247-262.
4. Hanauer SB, Sandborn WJ, Rutgeerts P, etal. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323-333.
5. Pouw MF, Krieckaert CL, Nurmohamed MT, etal. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis. Epub December 10, 2013.
6. Wong DR, Pierik M, Seinen ML, etal. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients. J Crohns Colitis. 2014;8(2):120-128.
7. Baert F, Noman M, Vermeire S, etal. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348(7):601-608.
8. Sandborn WJ, Rutgeerts P, Enns R, etal. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829-838.
9. Karmiris K, Paintaud G, Noman M, etal. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009;137(5):1628-1640.
10. Roblin X, Marotte H, Rinaudo M, etal. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12(1): 80-84.
11. Sandborn WJ, Hanauer SB, Rutgeerts P, etal. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232-1239.
12. Colombel JF, Sandborn WJ, Rutgeerts P, etal. Adalimumab for of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132(1):52-65.
13. Colombel JF, Schwartz DA, Sandborn WJ, etal. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009;58(7): 940-948.
14. Dewint P, Hansen BE, Verhey E, etal. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63(2):292-299.
15. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106(4):685-698.
16. D'Haens GR, Panaccione R, Higgins PD, etal. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106(2):199-212.
17. Allez M, Karmiris K, Louis E, etal. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010;4(4):355-366.
18. Siegel CA, Melmed GY. Predicting response to Anti-TNF Agents for the treatment of crohn's disease. Therap Adv Gastroenterol. 2009;2(4): 245-251.
19. Sandborn WJ, Colombel JF, Enns R, etal; International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353(18):1912-1925.
20. Sandborn WJ, Feagan BG, Rutgeerts P, etal; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8):711-721.
21. Ho GT, Smith L, Aitken S, etal. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther. 2008;27(4):308-315.
22. Allez M, Vermeire S, Mozziconacci N, etal. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010;31(1): 92-101.
23. Chaparro M, Andreu M, Barreiro-de Acosta M, etal. Effectiveness of infliximab after adalimumab failure in Crohn's disease. World J Gastroenterol. 2012;18(37):5219-5224.
24. Hanauer SB, Feagan BG, Lichtenstein GR, etal; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 4 2002;359(9317):1541-1549.
25. Schreiber S, Khaliq-Kareemi M, Lawrance IC, etal; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357(3):239-250.
26. Jones J, Loftus EV Jr, Panaccione R, etal. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2008;6(11):1218-1224.
27. Henriksen M, Jahnsen J, Lygren I, etal; IBSEN Study Group. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57(11):1518-1523.
28. Kiss LS, Szamosi T, Molnar T, etal; Hungarian IBD Study Group. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther. 2011;34(8):911-922.
29. Mao R, Xiao YL, Gao X, etal. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18(10):1894-1899.
30. Molander P, Björkesten CG, Mustonen H, etal. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis. 2012;18(11):2011-2017.
31. Colombel JF, Sandborn WJ, Reinisch W, etal; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362(15):1383-1395.
32. Chiu YL, Rubin DT, Vermeire S, etal. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis. 2013;19(6):1112-1122.
33. Afif W, Loftus EV Jr, Faubion WA, etal. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(5): 1133-1139.
34. Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis. 2013;19(7):1528-1533.
35. Sandborn WJ, Colombel JF, Schreiber S, etal. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis. 2011;17(1): 141-151.
36. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol. 2011;106(4):674-684.
37. Baert F, Glorieus E, Reenaers C, etal; BIRD (Belgian IBD Research and Development). Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. J Crohns Colitis. 2013;7(2):154-160.
38. Louis E, Mary JY, Vernier-Massouille G, etal; Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142(1):63-70.
39. Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol. 2013;32(10):1429-1435.
40. West RL, Zelinkova Z, Wolbink GJ, etal. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther. 2008;28(9):1122-1126.
41. de Silva PS, Nguyen DD, Sauk J, Korzenik J, Yajnik V, Ananthakrishnan AN. Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36(5):459-466.
42. Brandse JF, Peters CP, Gecse KB, etal. Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's disease. Inflamm Bowel Dis. 2014;20(2): 251-258.
43. Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13(1):24-30.
44. Chowers Y, Sturm A, Sans M, etal. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis. 2010;4(4):367-376.
45. Finckh A, Ciurea A, Brulhart L, etal; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 2007;56(5):1417-1423.
46. Genovese MC, Becker JC, Schiff M, etal. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114-1123.
47. Sandborn WJ, Gasink C, Gao LL, etal; CERTIFI Study Group. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012;367(16):1519-1528.
48. Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012;10(9): 1002-1007.
49. Reenaers C, Louis E, Belaiche J, Seidel L, Keshav S, Travis S. Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab? Aliment Pharmacol Ther. 2012;36(11-12):1040-1048.